Literature DB >> 10198796

Vaccination as a modality to prevent Lyme disease. A status report.

G P Wormser1.   

Abstract

Recombinant outer surface protein A (OspA) of Borrelia burgdorferi is a highly protective immunogen for prevention of Lyme disease in experimental animals. Humoral immunity is sufficient for protection. The principal mechanism of action is prevention of transmission of the spirochete from tick to host. A recombinant OspA vaccine has been licensed for use in dogs. The recent licensure of an OspA vaccine for humans resulted from a critical analysis of recently completed efficacy studies.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10198796     DOI： 10.1016/s0891-5520(05)70047-7

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  4 in total

1.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.

Authors:  Jerilyn R Izac; Lee D Oliver; Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2017-05-04       Impact factor: 3.641

3.  Do antiborrelial antibodies suggest Lyme disease in Cuba?

Authors:  Islay Rodríguez; Carmen Fernández; Marina Cinco; Rodobaldo Pedroso; Omar Fuentes
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

4.  Robust B Cell Responses Predict Rapid Resolution of Lyme Disease.

Authors:  Lisa K Blum; Julia Z Adamska; Dale S Martin; Alison W Rebman; Serra E Elliott; Richard R L Cao; Monica E Embers; John N Aucott; Mark J Soloski; William H Robinson
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.